Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
Erasca and Bristol Myers Squibb announced a clinical trial collaboration to evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with BMS's PRMT5 inhibitor navlimetostat for MTAP-deleted pancreatic cancer. BMS will sponsor the Phase 1/2 trial while Erasca supplies ERAS-0015. The combination targets the dependency created by co-occurring RAS mutations in nearly all MTAP-deleted pancreatic cancers.



